Related Experiment Videos
Panel discussion. I: Cost effectiveness of drug development and health economics
B A Brody1, A R Feinstein, C D Furberg
1Baylor College of Medicine, Houston.
Arzneimittel-Forschung
|August 1, 1989
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE.
Journal of chronic diseases·2015
The Blame-X syndrome: problems and lessons in nosology, spectrum, and etiology.
Journal of clinical epidemiology·2001
Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer.
Annals of epidemiology·2001
A rating system for prompt clinical diagnosis of ischemic stroke.
Archives of medical research·2001
Leave-one-out procedure in the validation of elimination rate constant analysis.
Arzneimittel-Forschung·2012
Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study.
Arzneimittel-Forschung·2012
Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital.
Journal of comparative effectiveness research·2026
Addressing the failure of economic measures of value-for-money to reflect societal preferences for health and social care.
Journal of health services research & policy·2026
Establishing multiple cost-effectiveness thresholds in Oman: a stakeholder-driven approach.
Health economics review·2026
Fever of unknown origin: cost of illness study.
Open medicine (Warsaw, Poland)·2026